| 0.3955 -0.083 (-17.41%) | 10-09 15:40 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.66 | 1-year : | 0.77 |
| Resists | First : | 0.56 | Second : | 0.66 |
| Pivot price | 0.24  |
|||
| Supports | First : | 0.31 | Second : | 0.15 |
| MAs | MA(5) : | 0.34 |
MA(20) : | 0.23 |
| MA(100) : | 0.23 |
MA(250) : | 0.52 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 64.5 |
D(3) : | 70.7 |
| RSI | RSI(14): 69.3 |
|||
| 52-week | High : | 1.5 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PCSA ] has closed below upper band by 8.0%. Bollinger Bands are 282.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.57 - 0.57 | 0.57 - 0.57 |
| Low: | 0.45 - 0.45 | 0.45 - 0.45 |
| Close: | 0.48 - 0.48 | 0.48 - 0.48 |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Wed, 08 Oct 2025
Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight? - inkl
Tue, 02 Sep 2025
Processa Pharmaceuticals Adjourns Special Shareholder Meeting - TipRanks
Thu, 07 Aug 2025
Biotech Pioneer Processa Pharmaceuticals Embraces Crypto: Strategic Investment Meets Blockchain Innovation - Stock Titan
Fri, 11 Jul 2025
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress - Yahoo Finance
Mon, 30 Jun 2025
Processa Pharmaceuticals adjourns annual meeting due to lack of quorum - Investing.com
Tue, 17 Jun 2025
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 909 (K) |
| Shares Short P.Month | 1,740 (K) |
| EPS | -2.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -102.7 % |
| Return on Equity (ttm) | -212.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | 2.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|